CLINICAL_TRIALS ClinicalTrials.gov record update

A Single Arm, Open-label, Phase 2 Study to Assess the Efficacy and Safety of Lucitanib Given Orally as a Single Agent to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02109016
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:12.976456+00:00
Published At: 2019-07-29T00:00:00+00:00
Record Updated At: 2019-07-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non-Small Cell Lung Cancer", "Squamous Non-Small Cell Lung Cancer", "NSCLC", "Small Cell Lung Cancer", "SCLC", "Lung Cancer", "Advanced Lung Cancer", "Metastatic Lung Cancer", "Stage IV Lung Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-07-29"
protocolSection.identificationModule.nctId: "NCT02109016"
protocolSection.identificationModule.officialTitle: "A Single Arm, Open-label, Phase 2 Study to Assess the Efficacy and Safety of Lucitanib Given Orally as a Single Agent to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.